(4-isopentyloxyphenyl)methanamine | 21244-38-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-isopentyloxyphenyl)methanamine
• 英文别名: 4-isopentyloxy-benzylamine；p-(3-methylbutoxy)benzylamine；4-(3-Methyl-butoxy)-benzylamine；[4-(3-methylbutoxy)phenyl]methanamine
• CAS: 21244-38-2
• 化学式: C₁₂H₁₉NO
• mdl: MFCD02225921
• 分子量: 193.289
• InChiKey: VBNCKGMOSXBVRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (4-isopentyloxyphenyl)methanamine 、 2-(3-pyridyl)thiazolidine-4-carboxylic acid 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 为溶剂， 生成 (R)-2-Pyridin-3-yl-thiazolidine-4-carboxylic acid 4-(3-methyl-butoxy)-benzylamide
  参考文献：
  名称：

  2-(3-Pyridyl)thiazolidine-4-carboxamides. 1. Novel Orally Active Antagonists of Platelet-Activating Factor (PAF).

  摘要：

  在寻找新型血小板激活因子（PAF）拮抗剂的过程中，我们发现1-(3-苯基丙基)-4-[2-(3-吡啶基)噻唑烷-4-羧基]哌嗪（3%）表现出体外和体内的PAF拮抗活性。在3x的苄基亚甲基碳上引入功能团，获得了一些比3x更具活性的化合物。其中，1-(3-甲基-3-苯基丁基)-4-[2-(3-吡啶基)噻唑烷-4-羧基]-哌嗪富马酸盐（3al，YM264）被发现是效果最强的PAF拮抗剂之一。

  DOI：

  10.1248/cpb.45.1659
• 作为产物：
  描述：

  (4-chloromethyl-phenyl)-isopentyl ether 在 氨 作用下， 生成 (4-isopentyloxyphenyl)methanamine
  参考文献：
  名称：

  Mndshojan; Babijan, Izvestiya Akademii Nauk Armyanskoi SSR, Khimicheskie Nauki, 1958, vol. 11, p. 351,353,354

  摘要：

  DOI：

文献信息

• Saturated heterocyclic carboxamide derivatives
  申请人：Yamanouchi Pharmaceutical Co., Ltd.

  公开号：US04987132A1

  公开（公告）日：1991-01-22

  A saturated heterocyclic carboxamide derivative of the following general formula (I) and salts thereof which have platelet activating factor (PAF) antagonizing activity. ##STR1##

  以下是通用公式（I）的饱和杂环羧酰胺衍生物及其盐，具有血小板活化因子（PAF）拮抗活性。
• [EN] ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'ADÉNINE EN TANT QU'INHIBITEURS DE PROTÉINE KINASES
  申请人：BCI PHARMA

  公开号：WO2017191297A1

  公开（公告）日：2017-11-09

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N- oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3', R4, R4', X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及一种适用于作为激酶抑制剂的化合物，其符合一般式(I) [化合物(C)，以下简称]，或其N-氧化物、药学上可接受的盐、药学上可接受的溶剂，或其立体异构体，式(I)中A、R1、R2、R3、R3'、R4、R4'、X、Y、Z、T的定义如权利要求所述。本发明还涉及一种体外抑制蛋白激酶活性的方法，包括将蛋白激酶与式(I)的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶剂，或其立体异构体接触。本发明还涉及式(I)的化合物本身，以及其作为药物的用途，以及用于治疗由蛋白激酶介导的疾病的方法，所述疾病包括癌症、炎症性疾病、心血管疾病、病毒感染性疾病、循环系统疾病、纤维增殖性疾病和疼痛敏化性疾病。
• Adenine derivatives as protein kinase inhibitors
  申请人：B.C.I. PHARMA

  公开号：US11236093B2

  公开（公告）日：2022-02-01

  The present invention relates to a compound suitable for use as a kinase inhibitor according to general formula (I) [compound (C), herein after], or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof, formula (I) wherein A, R1, R2, R3, R3′, R4, R4′, X, Y, Z, T are as defined in the claims. The invention further relates to an in vitro method of inhibiting protein kinase activity which comprises contacting a protein kinase with a compound of formula (I), or the N-oxide, pharmaceutically acceptable salt, pharmaceutically acceptable solvate, or stereoisomer thereof. The invention further relates to the compounds of formula (I) per se, as well as to their use as a medicament, and for use or in a method of treatment of a disease mediated by a protein kinase selected from cancer, inflammatory disorders, cardiovascular diseases, viral induced diseases, circulatory diseases, fibro-proliferative diseases and pain sensitization disorders.

  本发明涉及根据通式(Ⅰ)[化合物(C)，以下同]的适于用作激酶抑制剂的化合物，或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体，式(Ⅰ)其中A、R1、R2、R3、R3′、R4、R4′、X、Y、Z、T如权利要求书中所定义。本发明进一步涉及一种抑制蛋白激酶活性的体外方法，该方法包括使蛋白激酶与式(I)化合物或其N-氧化物、药学上可接受的盐、药学上可接受的溶液或立体异构体接触。本发明进一步涉及式（I）化合物本身及其作为药物的用途，以及用于治疗由蛋白激酶介导的选自癌症、炎症性疾病、心血管疾病、病毒引起的疾病、循环系统疾病、纤维增生性疾病和痛觉过敏性疾病的方法。
• ADENINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：B.C.I. Pharma

  公开号：EP3452477A1

  公开（公告）日：2019-03-13
• US4987132A
  申请人：——

  公开号：US4987132A

  公开（公告）日：1991-01-22